These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31312712)

  • 21. Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?
    González-Martín A; Sánchez-Lorenzo L
    Cancer; 2019 Dec; 125 Suppl 24():4616-4622. PubMed ID: 31967676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers.
    Lee EK; Konstantinopoulos PA
    Ther Adv Med Oncol; 2020; 12():1758835920944116. PubMed ID: 32782491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy.
    Cho Y; Milane L; Amiji MM
    Expert Opin Biol Ther; 2019 Jun; 19(6):547-560. PubMed ID: 30933545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies.
    Ring KL; Pakish J; Jazaeri AA
    Cancer J; 2016; 22(2):101-7. PubMed ID: 27111905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies.
    Pan K; Gong J; Huynh K; Cristea M
    Target Oncol; 2019 Jun; 14(3):269-283. PubMed ID: 31069647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future.
    Yamashita H; Nakayama K; Ishikawa M; Ishibashi T; Nakamura K; Sawada K; Yoshimura Y; Tatsumi N; Kurose S; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31623180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
    Mirza MR; Pignata S; Ledermann JA
    Ann Oncol; 2018 Jun; 29(6):1366-1376. PubMed ID: 29750420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.
    Menderes G; Hicks C; Black JD; Schwab CL; Santin AD
    Expert Opin Biol Ther; 2016 Aug; 16(8):989-1004. PubMed ID: 27070175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immuno-oncology for Gynecologic Malignancies.
    How J; Patel A; Jazaeri A
    Adv Exp Med Biol; 2020; 1244():149-182. PubMed ID: 32301014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
    Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
    Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immune checkpoint (PD-1 and CTIA-4) signal inhibitors for gynecologic oncology; up to date].
    Hamanishi J; Mandai M; Konishi I
    Nihon Rinsho; 2017 Feb; 75(2):234-244. PubMed ID: 30562858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic-Based Therapy of Gynecologic Malignancies.
    Markman M
    Acta Med Acad; 2019 Apr; 48(1):84-89. PubMed ID: 31264436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
    Li K; Tian H
    J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
    Rajani KR; Vile RG
    Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARP Inhibitors in Epithelial Ovarian Cancer.
    Taylor KN; Eskander RN
    Recent Pat Anticancer Drug Discov; 2018; 13(2):145-158. PubMed ID: 29205122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations.
    Baksh K; Weber J
    Semin Oncol; 2015 Jun; 42(3):363-77. PubMed ID: 25965355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
    Wang Z; Sun K; Xiao Y; Feng B; Mikule K; Ma X; Feng N; Vellano CP; Federico L; Marszalek JR; Mills GB; Hanke J; Ramaswamy S; Wang J
    Sci Rep; 2019 Feb; 9(1):1853. PubMed ID: 30755715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
    Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncolytic virus and PD-1/PD-L1 blockade combination therapy.
    Chen CY; Hutzen B; Wedekind MF; Cripe TP
    Oncolytic Virother; 2018; 7():65-77. PubMed ID: 30105219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.